A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease.

Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group. J Hepatol. 2023 Jun 5:S0168-8278(23)00342-2. doi: 10.1016/j.jhep.2023.05.013.